For the year ending 2025-12-31, CBIO has $240,293K in assets. $37,281K in debts. $213,192K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 213,192 | |||
| Accounts receivable, net | 18,000 | |||
| Prepaid expenses and other current assets | 5,463 | |||
| Total current assets | 236,655 | |||
| Property and equipment, net | 846 | |||
| Operating lease right-of-use assets | 1,469 | |||
| Restricted cash | 107 | |||
| Other assets | 1,216 | |||
| Total assets | 240,293 | |||
| Accounts payable-Nonrelated Party | 9,997 | |||
| Accrued expenses and other current liabilities-Nonrelated Party | 16,344 | |||
| Related party accounts payable and other current liabilities-Related Party | 140 | |||
| Deposit liability | 5,000 | |||
| Deferred revenue | 4,156 | |||
| Operating lease liability, current | 435 | |||
| Warrant liability, related party | 0 | |||
| Total current liabilities | 36,072 | |||
| Operating lease liability, noncurrent | 1,209 | |||
| Notes payable, noncurrent | 0 | |||
| Total liabilities | 37,281 | |||
| Series a non-voting convertible preferred shares, 0.001 par value 2,890 shares and no shares authorized as of december 31, 2025 and december 31, 2024, respectively 2,890 shares and no shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively-Series APreferred Stock | 4,000 | |||
| Ordinary shares, 0.001 par value shares and 40,000,000 shares authorized as of december 31, 2025 and december 31, 2024, respectively and shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively | 28 | |||
| Additional paid-in capital | 370,793 | |||
| Accumulated deficit | -171,809 | |||
| Total shareholders' equity (deficit) | 203,012 | |||
| Total liabilities, convertible preferred shares, and shareholders equity (deficit) | 240,293 | |||
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)